Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
There are still no established protocols for maintenance therapy with intravenous or oral
vitamin D preparations after the iPTH target has been achieved.
Therefore, the present study compared the efficacy of two maintenance therapy protocols,
i.e., oral administration of alfacalcidol (an oral vitamin D preparation) at a dose of 1.0
ug/day (higher-dose group) or at a dose of 0.25 ug/day (lower-dose group), in patients with
secondary hyperparathyroidism who responded to initial maxacalcitol therapy, resulting in the
control of iPTH to < 150 pg/mL.